Effect of zinc supplementation versus control group on cellular immunity, treatment and relapse of brucellosis

Effect of zinc supplementation versus control group on cellular immunity, treatment, and relapse of brucellosis: a single-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N332

Enrollment

Registered

2020-01-11

Start date

2020-03-05

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis. Brucellosis

Interventions

Intervention 1: Intervention group: Routine treatment brucellosis plus Zinc gluconate tablet (manufactured by Darukadeh Pharmaciutical Co.) 30 mg daily for 8 weeks. Intervention 2: Control group: Rout

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age of 15 to 60 years, Acute brucellosis

Exclusion criteria

Exclusion criteria: Pregnancy, History of brucellosis, Complicated brucellosis, Chronic diseases such as cardiovascular disease, anemia, bone carcinoma, Concurrent with AIDS, A history of collagen vascular disease, A history of zinc use

Design outcomes

Primary

Measure	Time frame
Clinical symptoms. Timepoint: Before the intervention and 1 and 2 months later. Method of measurement: By taking history and physical examination.;Treatment of the disease. Timepoint: 1 and 2 months after the intervention. Method of measurement: by using 2ME test.;Relapse of the disease. Timepoint: 6 months after the intervention. Method of measurement: by using 2ME test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fariba Keramat

Hamedan University of Medical Sciences

faribakeramat@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026